CLDX Celldex Therapeutics, Inc.

-0.01  -0%
Previous Close 2.62
Open 2.65
Price To book 1.31
Market Cap 326.52M
Shares 125,104,000
Volume 1,093,334
Short Ratio 10.72
Av. Daily Volume 2,058,430

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiated July 2016. Phase 1 dose-escalation portion of the study will complete enrollment by year-end 2017.
Renal cell carcinoma (RCC) - cancer
Phase 2 initiated April 2016. Enrollment to be completed 1Q 2018.
Varlilumab and nivolumab
Solid tumors - cancer
Noted March 14, 2017 that development will not be advanced to Phase 2
Varlilumab and atezolizumab (anti-PDL1)
Renal cell carcinoma (RCC) cancer
Noted March 14, 2017 that development will not be advanced to Phase 2
Varlilumab and sunitinib (Sutent)
Clear cell renal cell carcinoma (CC-RCC) cancer
Phase 1/2 commenced April 2016
Glembatumumab vedotin
Squamous cell lung cancer
Trial discontinued early March 2016 as unlikely to meet primary endpoint
CDX-110 rindopepimut - ACT IV
Cancer- glioblastoma multiforme (GBM) front line
Phase 2b enrollment to be completed by the end of September 2017.
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2 continues to enroll. Glembatumumab vedotin and varlilumab arm data due fall of 2017.
Glembatumumab vedotin, varlilumab, Opdivo or Keytruda
Cancer - melanoma

Latest News

  1. 3 Stocks That Could Double Your Money
  2. 3 Stocks with Universal Display-like Return Potential
  3. Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team
  4. Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report?
  5. 3 Beaten-Up Biotech Stocks: Are They Bargains?
  6. 3 Stocks That Look Just Like Oracle in 1986
  7. Today's Research Reports on Stocks to Watch: Celldex Therapeutics and Pandora Media
  8. Here's Why Celldex Therapeutics, Inc. Fell Today
  9. Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference
  10. Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting
  11. Here's What Shaved 14% Off Celldex Therapeutics, Inc.'s Stock Price in May
  12. ETFs with exposure to Celldex Therapeutics, Inc. : June 5, 2017
  13. Celldex Presents Promising Overall Survival Data from Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma
  14. Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
  15. Celldex Therapeutics, Inc.: The Bear Case from a Bull
  16. George O. Elston Named Chief Executive Officer of 2X Oncology
  17. Celldex's Immuno-Oncology Pipeline Continues to Impress
  18. Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc.
  19. 3 Value Stocks for Bold Investors
  20. Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting